Glossary

Stack Cycle

Updated February 28, 2026

A stack cycle is the structured, repeatable sequence of phases that governs how a supplement protocol is run, evaluated, and either renewed or retired. At its most basic: you run the stack, you rest and review, you decide what comes next. Done well, this rhythm is what separates a deliberate protocol from an indefinite habit you've stopped paying attention to.

Why cycles exist

Your body adapts. Receptors downregulate, enzymes upregulate, and the measurable effect of many compounds drifts from their baseline impact over weeks to months of continuous exposure. A cycle forces a structured break in that drift — giving you both a physiological reset and, just as importantly, a clean moment to ask whether the stack is actually doing what you think it is.

Cycles also create accountability. Without a defined endpoint, it's easy to carry forward a protocol that stopped working, or worse, one that's producing low-grade adverse effects you've normalized. The review phase exists specifically to catch that.

Anatomy of a cycle

Run phase This is the active window: you're taking the stack at target doses, logging symptoms, tracking relevant biomarkers or performance metrics, and noting adherence. The run phase is only useful if you're actually collecting data during it, not just taking capsules. Some protocols begin with a loading phase to establish tissue saturation before transitioning to standard dosing.

Washout and review The washout period is a rest window, typically ranging from a few days to several weeks depending on the half-life and mechanism of the compounds involved. Stimulatory compounds, adaptogens, hormonal modulators, and creatine-adjacent protocols all have meaningfully different washout requirements. This is your off cycle — a deliberate break that allows both physiological reset and objective assessment. During this window you conduct a structured review: did outcomes improve? Were adverse effects present, tolerable, or escalating? Did you actually adhere to the protocol?

Transition decision Based on the review, you make one of three calls: continue with the same protocol, adjust doses or compounds, or pause entirely. This decision should be documented, not assumed. The transition moment is the highest-leverage point in any supplement protocol — and the one most people skip. If continuing, you'll typically enter a maintenance phase with established dosing rather than repeating the loading protocol.

What makes a cycle go wrong

The most common failure is entering a new run phase without completing the washout review. It feels harmless — you're just continuing something that seemed fine — but you lose the reset value and compound any unresolved issues into the next window.

A close second is dose escalation across cycles without confirmed outcomes. If the first cycle produced a modest benefit at a lower dose, that's not automatically a reason to increase the dose in cycle two. Escalation should follow evidence, not optimism.

Carrying untracked side effects into a fresh cycle is also a meaningful risk. Minor sleep disruption, appetite changes, or GI irregularity can be easy to dismiss in isolation but may signal something worth addressing before continuing.

Progression criteria

A cycle earns a renewal when three conditions are met:

• There is measurable or clearly perceived improvement consistent with the stack's intended effect
• The adverse profile has been stable and manageable — no escalating symptoms, no new flags
• A documented decision has been made at the close of the prior cycle

If any of those conditions is uncertain, the cycle should pause, not proceed.

A note on cycle length

Optimal cycle length is genuinely compound-dependent and, for many less-studied ingredients, not well established in the literature. Common frameworks range from four to twelve weeks on, with washout periods scaled to roughly one quarter to one half of the run duration — but these are working heuristics, not clinical standards. The honest answer is that evidence on washout sufficiency is thin, particularly for users with highly variable routines, body compositions, or concurrent medication use.

Before you start your next cycle

Complete one structured decision checkpoint. Document your outcome data, your adherence rate, and your tolerance assessment. If you can't answer those three things clearly, you're not ready to restart — you're just continuing.

If adverse trends have persisted across two full cycles, that's the threshold for requesting clinician oversight before proceeding. This isn't a formality. Two cycles of signals is a pattern.